Perseus Proteomics Inc.
Fiscal Year Ending March 2027 Q2 Financial Results Presentation
Disclosed the financial overview and financial condition for FY ending March 2027 Q2. Revenue declined year-over-year and net income posted a loss. Explained profit and loss fluctuations reflecting R&D expenditures and grant impacts. Also presented pipeline progress and growth strategy going forward.
Key Figures
- Revenue: Unknown
- Net Income Attributable to Owners of Parent: -379 million yen
- Cash and Cash Equivalents, Ending Balance: 1,420 million yen
AI要約
Overview of Results
In the FY ending March 2027 Q2 results, revenue decreased year-over-year, and net income was in deficit due to research and development expenditures and the impact of grants. Financially, cash was reported at an ending balance of 1,420 million yen and the equity ratio was 62.7%. Derivation activities and clinical development progress centered on PPMX-T003/T002 were also disclosed, indicating completion of non-GLP toxicity tests and ongoing clinical trial progress.
Outlook and Strategy
As a growth strategy, we will strengthen integration of antibody acquisition technologies and AI-driven drug discovery to expand the drug discovery pipeline and enter new areas. Emphasis will be placed on expanding collaborative research, accelerating derivation and clinical development using phage libraries, and progress of investigator-initiated trials. External support developments such as AMPED will also be closely monitored.
Perseus Proteomics Inc.
Company overview · Stock price · Financial data · All IR